A lipoxygenase inhibitor that interferes with the action of arachidonate 5-lipoxygenase (EC 1.13.11.34).
| Member | Definition | Class |
|---|
| aa 861 | A member of the class of benzoquinones that is p-benzoquinone in which the hydrogens are substituted by three methyl groups and a 12-hydroxydodeca-5,10-diyn-1-yl group. | docebenone |
| alminoprofen | A substituted aniline that is ibuprofen in which the isobutyl group is replaced by a (2-methylprop-2-en-1-yl)amino group. A non-steroidal anti-inflammatory drug, it is used for treatment of inflammatory and rheumatic disorders. | alminoprofen |
| azelastine | A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position. | azelastine |
| azelastine hydrochloride | The hydrochloride salt of azelastine. | azelastine hydrochloride |
| benoxaprofen | A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals. | benoxaprofen |
| bw b70c | A hydroxamic acid that is urea in which both the hydrogens attached to one of the nitrogens are replaced by a hydroxy and a (1E)-1-[3-(4-fluorophenoxy)phenyl]but-1-en-3-yl group. A selective inhibitor of arachidonate 5-lipoxygenase, it can be used for the treatment of asthma. | BW B70C |
| caffeic acid | A hydroxycinnamic acid that is cinnamic acid in which the phenyl ring is substituted by hydroxy groups at positions 3 and 4. It exists in cis and trans forms; the latter is the more common. | caffeic acid |
| e 3040 | A member of the class of benzothiazoles that is 1,3-benzothiazole substituted by a methylnitrilo group, (pyridin-3-yl)methyl group, methyl group, hydroxy group and methyl group at position 2,4,5,6 and 7, respectively. It is a dual inhibitor of 5-lipoxygenase and thromboxane A2 synthetase and exhibits anti-inflammatory properties. The drug was being developed by Eisai (Tokyo, Japan) for the treatment of bowel disease. | E3040 |
| ebselen | A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase. | ebselen |
| eupatilin | A trimethoxyflavone that is flavone substituted by hydroxy groups at C-5 and C-7 and methoxy groups at C-6, C-3' and C-4' respectively. Isolated from Citrus reticulata and Salvia tomentosa, it exhibits anti-inflammatory, anti-ulcer and antineoplastic activities. | eupatilin |
| ginkgetin | A biflavonoid that is the 7,4'-dimethyl ether derivative of amentoflavone. Isolated from Ginkgo biloba and Dioon, it exhibits anti-HSV-1, antineoplastic and inhibitory activities towards arachidonate 5-lipoxygenase and cyclooxygenase 2. | ginkgetin |
| l 663536 | A member of the class of indoles that is 1H-indole substituted by a isopropyl group at position 5, a tert-butylsulfanediyl group at position 3, a 4-chlorobenzyl group at position 1 and a 2-carboxy-2-methylpropyl group at position 2. It acts as an inhibitor of arachidonate 5-lipoxygenase. | 3-[3-(tert-butylsulfanyl)-1-(4-chlorobenzyl)-5-(propan-2-yl)-1H-indol-2-yl]-2,2-dimethylpropanoic acid |
| meclofenamate sodium anhydrous | A hydrate that is the monohydrate of the sodium salt of meclofenamic acid. It is used for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | sodium meclofenamate monohydrate |
| meclofenamic acid | An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis. | meclofenamic acid |
| sulindac sulfone | A sulfone metabolite of sulindac that inhibits cell growth by inducing apoptosis independently of cyclooxygenase inhibition. It inhibits the development and induces regression of premalignant adenomatous polyps. Lipoxygenase and Cox-2 inhibitor. | sulindac sulfone |
| zileuton | A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogen at position 2 is replaced by a 1-[carbamoyl(hydroxy)amino]ethyl group. A selective 5-lipoxygenase inhibitor, it inhibits the formation of leukotrienes LTB4, LTC4, LDT4, and LTE4. It is used for the management of chronic asthma. | zileuton |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1 | Homo sapiens (human) | Potency | 10.6048 | 1 | 5 |
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 5.7626 | 1 | 4 |
| 2,3-bisphosphoglycerate-independent phosphoglycerate mutase | Leishmania major strain Friedlin | Potency | 7.5686 | 1 | 1 |
| 67.9K protein | Vaccinia virus | Potency | 15.8489 | 1 | 1 |
| acetylcholinesterase | Homo sapiens (human) | Potency | 15.1890 | 4 | 5 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 8.0910 | 1 | 7 |
| alpha-galactosidase | Homo sapiens (human) | Potency | 24.9765 | 3 | 3 |
| Alpha-synuclein | Homo sapiens (human) | Potency | 8.9553 | 1 | 4 |
| Amyloid-beta precursor protein | Homo sapiens (human) | Potency | 16.3601 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 24.8297 | 8 | 13 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 24.9661 | 2 | 8 |
| arylsulfatase A | Homo sapiens (human) | Potency | 19.5178 | 1 | 2 |
| ATAD5 protein, partial | Homo sapiens (human) | Potency | 15.4976 | 3 | 6 |
| Ataxin-2 | Homo sapiens (human) | Potency | 19.9526 | 1 | 1 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 10.3600 | 3 | 4 |
| atrial natriuretic peptide receptor 1 precursor | Homo sapiens (human) | Potency | 6.7456 | 1 | 1 |
| atrial natriuretic peptide receptor 2 precursor | Homo sapiens (human) | Potency | 26.1216 | 1 | 1 |
| Bloom syndrome protein isoform 1 | Homo sapiens (human) | Potency | 28.6819 | 2 | 6 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 30.4473 | 1 | 3 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 24.4039 | 1 | 4 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 23.7296 | 2 | 3 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 13.8401 | 1 | 6 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 57.1220 | 2 | 2 |
| Chain A, Cruzipain | Trypanosoma cruzi | Potency | 28.1838 | 1 | 1 |
| Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 22.7431 | 2 | 4 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 6.6242 | 2 | 7 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 24.3616 | 1 | 2 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 24.5884 | 2 | 5 |
| Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 20.9828 | 3 | 7 |
| Chain A, TYROSYL-DNA PHOSPHODIESTERASE | Homo sapiens (human) | Potency | 9.3846 | 1 | 11 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 6.6242 | 2 | 7 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 18.9482 | 2 | 5 |
| cytochrome P450 2C19 precursor | Homo sapiens (human) | Potency | 2.2409 | 1 | 3 |
| cytochrome P450 2C9 precursor | Homo sapiens (human) | Potency | 3.9879 | 1 | 5 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 20.7689 | 1 | 3 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 2.7570 | 1 | 2 |
| cytochrome P450 2D6 isoform 1 | Homo sapiens (human) | Potency | 14.2076 | 1 | 3 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 12.3183 | 2 | 14 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 11.6612 | 2 | 5 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 29.8493 | 1 | 2 |
| D(1A) dopamine receptor | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| D(1A) dopamine receptor | Sus scrofa (pig) | Potency | 26.1216 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| DNA dC->dU-editing enzyme APOBEC-3F isoform a | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| DNA polymerase beta | Homo sapiens (human) | Potency | 24.8119 | 1 | 4 |
| DNA polymerase eta isoform 1 | Homo sapiens (human) | Potency | 0.3162 | 1 | 1 |
| DNA polymerase III, partial | Bacillus subtilis | Potency | 4.7444 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 22.0915 | 1 | 4 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 14.1254 | 1 | 1 |
| endonuclease IV | Escherichia coli | Potency | 11.2202 | 1 | 1 |
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 1 | 1 |
| Endothelin-1 receptor | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 20.1631 | 8 | 16 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 27.0755 | 2 | 3 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 21.5345 | 8 | 13 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 9.4016 | 1 | 12 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 10.8928 | 4 | 8 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 51.9406 | 1 | 4 |
| fructose-bisphosphate aldolase A | Oryctolagus cuniculus (rabbit) | Potency | 22.3872 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 33.1734 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 20.7689 | 1 | 3 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 12.3183 | 1 | 7 |
| geminin | Homo sapiens (human) | Potency | 20.0309 | 4 | 14 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 10.1508 | 2 | 6 |
| glp-1 receptor, partial | Homo sapiens (human) | Potency | 12.0627 | 1 | 2 |
| GLS protein | Homo sapiens (human) | Potency | 10.1381 | 2 | 6 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 32.5597 | 1 | 3 |
| glucokinase regulatory protein | Homo sapiens (human) | Potency | 8.6438 | 1 | 2 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 29.8493 | 1 | 2 |
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| guanine nucleotide-binding protein G(i) subunit alpha-1 isoform 1 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| heat shock 70kDa protein 5 (glucose-regulated protein, 78kDa) | Homo sapiens (human) | Potency | 22.3872 | 1 | 1 |
| hexokinase-4 isoform 1 | Homo sapiens (human) | Potency | 8.6438 | 1 | 2 |
| Histamine H2 receptor | Cavia porcellus (domestic guinea pig) | Potency | 4.1553 | 2 | 21 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 6.3562 | 1 | 6 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 66.8968 | 1 | 2 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 20.7689 | 1 | 3 |
| huntingtin isoform 2 | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| hypothetical protein, conserved | Trypanosoma brucei | Potency | 11.1471 | 4 | 5 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 16.9301 | 1 | 1 |
| hypoxia-inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | Homo sapiens (human) | Potency | 12.1940 | 2 | 12 |
| IDH1 | Homo sapiens (human) | Potency | 19.1252 | 1 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 20.7689 | 1 | 6 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| Interferon beta | Homo sapiens (human) | Potency | 19.2947 | 2 | 4 |
| isocitrate dehydrogenase 1, partial | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 5.2766 | 1 | 6 |
| lethal factor (plasmid) | Bacillus anthracis str. A2012 | Potency | 10.6530 | 1 | 3 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 19.4852 | 3 | 7 |
| luciferase | Photuris pensylvanica (Pennsylania firefly) | Potency | 18.0789 | 3 | 5 |
| lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 19.0194 | 1 | 5 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 16.4877 | 2 | 15 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 29.7388 | 2 | 3 |
| muscarinic acetylcholine receptor M1 | Rattus norvegicus (Norway rat) | Potency | 8.9360 | 2 | 2 |
| muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 11.2202 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 10.9720 | 1 | 5 |
| NFKB1 protein, partial | Homo sapiens (human) | Potency | 13.3574 | 2 | 4 |
| nonstructural protein 1 | Influenza A virus (A/WSN/1933(H1N1)) | Potency | 18.7984 | 1 | 4 |
| Nrf2 | Homo sapiens (human) | Potency | 29.2278 | 2 | 3 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 26.4868 | 2 | 5 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 21.3318 | 2 | 8 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 23.4487 | 3 | 12 |
| Ornithine decarboxylase | Rattus norvegicus (Norway rat) | Potency | 10.0000 | 1 | 1 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 100.6342 | 1 | 3 |
| peptidyl-prolyl cis-trans isomerase NIMA-interacting 1 | Homo sapiens (human) | Potency | 37.9330 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 27.8702 | 1 | 3 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 68.0582 | 1 | 4 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 17.5654 | 3 | 3 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 24.8836 | 2 | 4 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 12.1344 | 1 | 5 |
| plasminogen precursor | Mus musculus (house mouse) | Potency | 11.9048 | 1 | 2 |
| polyprotein | Zika virus | Potency | 33.1734 | 1 | 1 |
| polyunsaturated fatty acid lipoxygenase ALOX12 | Homo sapiens (human) | Potency | 2.8371 | 1 | 2 |
| Polyunsaturated fatty acid lipoxygenase ALOX15B | Homo sapiens (human) | Potency | 4.5738 | 1 | 3 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 12.9363 | 1 | 5 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 21.5600 | 2 | 4 |
| progesterone receptor | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| pyruvate kinase | Leishmania mexicana mexicana | Potency | 15.5513 | 5 | 5 |
| pyruvate kinase PKM isoform a | Homo sapiens (human) | Potency | 5.1189 | 4 | 4 |
| pyruvate kinase PKM isoform b | Homo sapiens (human) | Potency | 10.0000 | 2 | 2 |
| Rap guanine nucleotide exchange factor 4 | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 20.2546 | 2 | 4 |
| regulator of G-protein signaling 4 | Homo sapiens (human) | Potency | 17.5440 | 1 | 3 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 30.7336 | 2 | 2 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 14.7158 | 2 | 4 |
| RGS12 | Homo sapiens (human) | Potency | 12.5893 | 1 | 1 |
| serine/threonine-protein kinase mTOR isoform 1 | Homo sapiens (human) | Potency | 20.0061 | 3 | 4 |
| serine/threonine-protein kinase PLK1 | Homo sapiens (human) | Potency | 12.0929 | 1 | 2 |
| Sigma non-opioid intracellular receptor 1 | Homo sapiens (human) | Potency | 5.7988 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 14.2733 | 2 | 3 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 14.2733 | 2 | 3 |
| Smad3 | Homo sapiens (human) | Potency | 19.5754 | 1 | 3 |
| Sodium channel protein type 1 subunit alpha | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Sodium channel protein type 2 subunit alpha | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Sodium channel protein type 3 subunit alpha | Rattus norvegicus (Norway rat) | Potency | 5.7988 | 1 | 1 |
| Spike glycoprotein | Severe acute respiratory syndrome-related coronavirus | Potency | 23.0602 | 1 | 2 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 20.9057 | 1 | 4 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 3.2957 | 1 | 2 |
| TDP1 protein | Homo sapiens (human) | Potency | 14.7789 | 2 | 20 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 26.7904 | 1 | 2 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 18.7632 | 3 | 9 |
| Thrombopoietin | Homo sapiens (human) | Potency | 3.1623 | 2 | 2 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 21.8409 | 2 | 6 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 12.2980 | 4 | 6 |
| transcriptional regulator ERG isoform 3 | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 31.6228 | 1 | 1 |
| tyrosine-protein kinase Yes | Homo sapiens (human) | Potency | 48.7315 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 7.9433 | 1 | 1 |
| urokinase plasminogen activator surface receptor precursor | Mus musculus (house mouse) | Potency | 11.9048 | 1 | 2 |
| urokinase-type plasminogen activator precursor | Mus musculus (house mouse) | Potency | 11.9048 | 1 | 2 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 50.5210 | 2 | 5 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 15.1332 | 2 | 2 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 8.5122 | 2 | 2 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 37.6422 | 1 | 9 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 29.8493 | 1 | 2 |